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EvidEncE-basEd answEr
A
	 Do	statins	increase	the	risk		
of	developing	diabetes?	
	 Yes.	 Statin	 therapy	 produces	 a	
	 small	 increase	 in	 the	 incidence	 of	
diabetes:	 one	 additional	 case	 per	 255	pa-
tients	 taking	statins	over	4	years	 (strength	
of	 recommendation	 [SOR]:	A,	 meta-anal-
ysis).	 Intensive	 statin	 therapy,	 compared	
with	moderate	therapy,	produces	an	addi-
tional	2	cases	of	diabetes	per	1000	patient	
years	 (SOR:	B,	meta-analysis	with	 signifi-
cant	heterogeneity	among	trials).	
Evidence summary
A	meta-analysis	of	13	randomized,	placebo-	
or	 standard	 of	 care-controlled	 statin	 trials	
(113,148	 patients,	 81%	 without	 diabetes	 at	
enrollment,	 mean	 ages	 55-76	 years)	 found	
that	 statin	 therapy	 increased	 the	 incidence	
of	 diabetes	 by	 9%	 over	 4	 years	 (odds	 ratio	
[OR]=1.09;	 95%	 confidence	 interval	 [CI],	
1.02-1.17),	 or	 one	 additional	 case	 per	
255	patients.1	The	 increased	 risk	was	 similar	
for	 lipophilic	 (pravastatin,	 rosuvastatin)	and	
hydrophilic	 (atorvastatin,	 simvastatin,	 lov-
astatin)	statins,	although	the	analysis	wasn’t	
adjusted	for	doses	used.	
In	 a	 meta-regression	 analysis,	 baseline	
body	 mass	 index	 or	 percentage	 change	 in	
low-density	 lipoprotein	 cholesterol	 didn’t	
appear	 to	 confer	 additional	 risk.	The	 risk	 of	
diabetes	 with	 statins	 was	 generally	 higher	
in	 studies	 with	 older	 patients	 (data	 given	
graphically).
Higher statin doses  
mean higher risk
A	 meta-analysis	 of	 5	 placebo	 and	 stan-
dard-of-care	 randomized	 controlled	 trials	
(39,612	patients,	83%	without	diabetes	at	en-
rollment,	mean	 age	 58-64	 years)	 found	 that	
the	 risk	 of	 diabetes	 was	 higher	 with	 high-
er-dose	 statins.2	 Therapy	 with	 atorvastatin	
80	mg	or	simvastatin	40	to	80	mg	was	defined	
as	 intensive.	 Treatment	 with	 simvastatin	
20	to	40	mg,	atorvastatin	10	mg,	or	pravastatin	
40	mg	was	defined	as	moderate.	
At	 a	 mean	 follow-up	 of	 4.9	 years,	 in-
tensive	 statin	 therapy	 was	 associated	
with	 a	 higher	 risk	 of	 developing	 diabetes	
than	 moderate	 therapy	 (OR=1.12;	 95%	 CI,	
1.04-1.22)	with	2	additional	cases	of	diabetes	per	
1000	 patient-years	 in	 the	 intensive	 therapy	
group.	The	authors	noted	significant	hetero-
geneity	 between	 trials	 with	 regard	 to	major	
cardiovascular	events.
Similar	results	were	found	in	a	subsequent	
population-based	cohort	study	of	471,250	non-
diabetic	patients	older	than	66	years	who	were	
newly	 prescribed	 a	 statin.3	The	 study	 authors	
used	the	incidence	of	new	diabetes	in	patients	
taking	pravastatin	as	the	baseline,	since	it	had	
been	 associated	with	 reduced	 rates	 of	 diabe-
tes	 in	a	 large	cardiovascular	prevention	 trial.4	
Without	 adjusting	 for	 dose,	 patients	 were	 at	
significantly	 higher	 risk	 of	 diabetes	 if	 pre-
scribed	 atorvastatin	 (hazard	 ratio	 [HR]=1.22;	
95%	CI,	1.15-1.29),	rosuvastatin	(HR=1.18;	95%	
CI,	1.10-1.26),	or	simvastatin	(HR=1.10;	95%	CI,	
1.04-1.17)	compared	with	pravastatin.	The	risk	
with	 fluvastatin	 and	 lovastatin	was	 similar	 to	
pravastatin.	
A	subanalysis	that	compared	moderate-	
and	 high-dose	 statin	 therapy	with	 low-dose	
therapy	 (atorvastatin	 <20	 mg,	 rosuvastatin	
<10	mg,	 simvastatin	<80	mg,	 or	 any	dose	of	
fluvastatin,	 lovastatin,	 or	 pravastatin)	 found	
Kristin Parker, DO;  
Karen Dohr, PharmD;  
Jon O. Neher, MD;  
Gary Kelsberg, MD
Valley Family Medicine  
Residency, Renton, Wash
Leilani St. Anna, MLIS, 
AHIP
University of Washington, 
Seattle
DEPuty EDItOR
Rick Guthmann, MD, 
MPH
Advocate Illinois Masonic 
Family Medicine  
Residency, Chicago
246 ThE jouRNAl oF FAmIly PRAcTIcE  |   APRIl 2015  |   Vol 64, No 4
clinical inquiries
References
a	 22%	 increased	 risk	 of	 diabetes	 (HR=1.22;	
95%	 CI,	 1.19-1.26)	 for	 moderate-dose	 ther-
apy	 (atorvastatin	 20-79	 mg,	 rosuvastatin	
10-39	 mg,	 or	 simvastatin	 >80	 mg)	 and	 a	
30%	increased	risk	(HR=1.3;	95%	CI,	1.2-1.4)	
for	high-dose	therapy	(atorvastatin	≥80	mg	or	
rosuvastatin	≥40	mg).
A cohort trial also shows  
increased diabetes risk
A	 smaller	 subsequent	 cohort	 trial	 based	 on	
data	from	Taiwan	National	Health	Insurance	
records	 compared	 8412	 nondiabetic	 adult	
patients	 (mean	 age	 63	 years)	 taking	 statins	
with	 33,648	 age-	 and	 risk-matched	 controls	
not	 taking	 statins	 over	 a	 mean	 duration	 of	
7.2	 years.5	 Statin	 use	 was	 associated	 with	
a	 15%	 higher	 risk	 of	 developing	 diabetes	
(HR=1.15;	95%	CI,	1.08-1.22).
Recommendations
The	 2013	 American	 College	 of	 Cardiology/
American	 Heart	 Association	 guidelines	 for	
lipid-lowering	 therapy	 recommend	 that	 pa-
tients	taking	statins	be	screened	for	diabetes	
according	 to	 current	 screening	 recommen-
dations.6	The	 guidelines	 advise	 encouraging	
patients	who	develop	diabetes	while	on	statin	
therapy	 to	adhere	 to	a	heart-healthy	dietary	
pattern,	 engage	 in	 physical	 activity,	 achieve	
and	maintain	 a	 healthy	 body	 weight,	 cease	
tobacco	 use,	 and	 continue	 statin	 therapy	 to	
reduce	the	risk	of	cardiovascular	events.					JFP
	 1.			Sattar	N,	Preiss	D,	Murray	HM,	et	al.	Statins	and	risk	of	incident	
diabetes:	a	collaborative	meta-analysis	of	randomised	statin	tri-
als.	Lancet.	2010;375:735-742.
	 2.			Preiss	 D,	 Seshasai	 SR,	 Welsh	 P,	 et	 al.	 Risk	 of	 incident	
diabetes	 with	 intensive-dose	 compared	 with	 moderate-
dose	 statin	 therapy:	 a	 meta-analysis.	 JAMA.	 2011;305:
2556-2564. 
	 3.			Carter	AA,	Gomes	T,	Camacho	X,	et	al.	Risk	of	incident	dia-
betes	among	patients	treated	with	statins:	population-based	
study.	BMJ.	2013;346:f2610.	
	 4.			Freeman	 DJ,	 Morrie	 J,	 Sattar	 N,	 et	 al.	 Pravastatin	 and	 the	
development	of	diabetes	mellitus:	evidence	 for	a	protective	
treatment	effect	in	the	West	of	Scotland	Coronary	Prevention	
Study.	Circulation. 2001;103:357-362.
	 5.			Wang	KL,	Liu	CJ,	Chao	TF,	et	al.	Statins,	risk	of	diabetes	and	
implications	 on	 outcomes	 in	 the	 general	 population.	 J Am 
Coll Cardiol.	2012;60:1231-1238.
	 6.			Stone	NJ,	Robinson	JG,	Lichtenstein	AH,	et	al;	American	Col-
lege	 of	 Cardiology/American	 Heart	 Association	 Task	 Force	
on	 Practice	 Guidelines.	 2013	 ACC/AHA	 guideline	 on	 the	
treatment	of	blood	cholesterol	to	reduce	atherosclerotic	car-
diovascular	risk	in	adults:	a	report	of	the	American	College	of	
Cardiology/American	Heart	Association	Task	Force	on	Prac-
tice	Guidelines.	Circulation.	2014;129:S1-S45.
MEDJOBNETWORK  com
Physician    NP/PA Career Center
The first mobile job board  
for Physicians, NPs, and PAs
Mobile Job Searches—access MedJobNetwork.com 
on the go from your smartphone or tablet
Advanced Search Capabilities—search for jobs 
by specialty, job title, geographic location,  
employer, and more
Scan this QR code  
to access the mobile version  
of MedJobNetwork.com
